IPOpulse
Back to Ticker

SBI Life Insurance Company Limited

NSE: SBILIFE
Insurance Life Insurance
₹1,717.6
-0.64%EOD · 11 Jun

SBI Life Insurance Company Limited is a listed Life Insurance company on NSE/BSE. Detailed profile data is being compiled — check BSE filings for the latest disclosures.

Market Cap
₹1.73 L Cr
52W Range
₹2132 / ₹1388
Volume
160K
1Y Return
-7.8%
P/E Ratio
72.5
P/B Ratio
9.4
ROE
13.7%

Peers in Insurance

Top 8 by market cap
CompanyLTP30DMarket CapP/EP/BROE %Div Yld %
SBI Life Insurance Company Limited(this stock)₹1,717.6₹1.73 L Cr72.59.413.7%0.15%
Life Insurance Corporation Of IndiaLICI₹393.8₹5.01 L Cr8.82.142.4%2.50%
HDFC Life Insurance Company LimitedHDFCLIFE₹546.5₹1.19 L Cr64.97.011.3%0.37%
ICICI Lombard General Insurance Company LimitedICICIGI₹1,725₹86,455 Cr31.95.517.9%0.80%

Technical Indicators

Full analysis · objective math, not advice
Returns
1D
-0.6%
1W
-3.7%
1M
-7.7%
3M
-6.3%
6M
-15.2%
1Y
-7.8%
Weinstein Stage
Stage 4 — Declining (downtrend)
RSI (14)
11 Oversold
Trend Template
2/7weak
Moving Averages (price vs MA)
20-DMA
₹1817
below
50-DMA
₹1833
below
150-DMA
₹1938
below
200-DMA
₹1924
below
From 52W High
-19.4%
From 52W Low
+23.7%
Support (20D)
1712
Resistance (20D)
1907

Technical indicators are objective calculations from historical EOD prices (RSI, moving averages, Weinstein stage, Minervini trend-template, relative strength). For educational reference only — not a buy/sell recommendation.

Quality Signals

Multi-year consistency · Source: Screener annual data
ROE Consistency
0/0 years ≥15%
Revenue Growth
+15.4% CAGR
Up 6 of last 11 years
Earnings Quality
Fully cash-backed
OCF / Net Profit = 13.98x · 12/12 yrs +ve cash flow

Quality signals derived from multi-year annual financials. ROE consistency = years with ≥15% return on equity. Cash-backed = operating cash flow vs reported net profit (≥1x means earnings are converted to real cash, not just accruals). Educational reference only — not investment advice.

Community discussion(0)

Sign in to join the discussion.

Sign in

No comments yet — be the first to share your view.